BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golder V, Tsang-A-Sjoe MWP. Treatment targets in SLE: remission and low disease activity state. Rheumatology (Oxford) 2020;59:v19-28. [PMID: 33280016 DOI: 10.1093/rheumatology/keaa420] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 van Schaik M, Arends EJ, Soonawala D, van Ommen E, de Leeuw K, Limper M, van Paassen P, Huizinga TWJ, Toes REM, van Kooten C, Rotmans JI, Rabelink TJ, Teng YKO. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. Trials 2022;23:939. [DOI: 10.1186/s13063-022-06874-w] [Reference Citation Analysis]
2 Kisaoglu H, Baba O, Kalyoncu M. Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis. Pediatr Nephrol 2022. [PMID: 36156735 DOI: 10.1007/s00467-022-05742-8] [Reference Citation Analysis]
3 Zinglersen AH, Drange IL, Myhr KA, Fuchs A, Pfeiffer-Jensen M, Brock C, Jacobsen S. Vagus nerve stimulation as a novel treatment for systemic lupus erythematous: study protocol for a randomised, parallel-group, sham-controlled investigator-initiated clinical trial, the SLE-VNS study. BMJ Open 2022;12:e064552. [PMID: 36127117 DOI: 10.1136/bmjopen-2022-064552] [Reference Citation Analysis]
4 Gerosa M, Beretta L, Ramirez GA, Bozzolo E, Cornalba M, Bellocchi C, Argolini LM, Moroni L, Farina N, Segatto G, Dagna L, Caporali R. Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort. JCM 2022;11:3587. [DOI: 10.3390/jcm11133587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Sagy I, Cohen Y, Nahum Y, Pokroy-Shapira E, Abu-Shakra M, Molad Y. Lower socioeconomic status worsens outcome of patients with systemic lupus erythematosus independently of access to healthcare. Lupus 2022;:9612033221084518. [PMID: 35341361 DOI: 10.1177/09612033221084518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Assunção H, Jesus D, Larosa M, Henriques C, Matos A, Le Guern V, Rubiño F, da Silva JAP, Rua-Figueroa I, Costedoat-Chalumeau N, Doria A, Inês LS. Definition of Low Disease Activity State based on the SLE-DAS: Derivation and validation in a multicentre real-life cohort. Rheumatology (Oxford) 2021:keab895. [PMID: 34864894 DOI: 10.1093/rheumatology/keab895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Robinson S, Thomas R. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front Immunol 2021;12:654701. [PMID: 34335564 DOI: 10.3389/fimmu.2021.654701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. Paediatr Drugs 2021;23:331-47. [PMID: 34244988 DOI: 10.1007/s40272-021-00457-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
9 Quartuccio L, De Marchi G, Azzolina D, Maresio E, Colatutto D, Binutti M, Monte M, Gallipoli S, Zobec F, Lanera C, Lorenzoni G, Palese A, Silano M, De Vita S, Gregori D. Psychological Effects of Lockdown Measures for the COVID-19 Outbreak in Patients with Systemic Lupus Erythematosus. J Multidiscip Healthc 2021;14:1475-88. [PMID: 34168460 DOI: 10.2147/JMDH.S311325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hoi AY, Morand EF. Treatment Update in Systemic Lupus Erythematous. Rheum Dis Clin North Am 2021;47:513-30. [PMID: 34215377 DOI: 10.1016/j.rdc.2021.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Tani C. Lupus in the 21st century. Rheumatology (Oxford) 2020;59:v1-3. [PMID: 33280010 DOI: 10.1093/rheumatology/keaa673] [Reference Citation Analysis]